Atopic Dermatitis | Regeneron | SOLO-CONTINUE
Pharmaceutical Company/Sponsor:
Regeneron
Code:
SOLO-CONTINUE
Title:
A phase 3, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of multiple dupilumab dose regimens administered as monotherapy for maintaining treatment response in patients with atopic dermatitis
Type:
Phase:
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Status:
Completed
Link for Additional Information:
